Sanofi SAN-1.02%decrease; red down pointing triangle posted better-than-expected earnings and sales in the third quarter, ...

Sanofi is now in “exclusive negotiations” with U.S. private equity firm Clayton, Dubilier & Rice (CD&R) to sell a 50% ...

Leerink Partners analyst David Risinger has maintained their bullish stance on SNYNF stock, giving a Buy rating yesterday. David Risinger has ...

and packaging of Sanofi’s SoloStar insulin pens and advanced insulin products. This strategic partnership reinforces our ...

As part of new agreements announced at the 7th edition of the Global Health Forum, Saudi Arabia signed deals to localize the ...

Sarclisa in combination with the VRd regiment was superior to VRd alone in improving survival in stem cell transplant ...

Confounding data from a Pfizer clinical trial have rattled the field of gene therapy for Duchenne muscular dystrophy ...

India’s powerful copycat pharmaceutical industry is set to roll out generic weight loss drugs in the U.K. within weeks ...

Sanofi will sell a 50% controlling stake in consumer healthcare unit Opella to private equity firm CD&R, with the French ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Today, there’s an immunoscience renaissance happening, and Sanofi is pushing medical research in this field forward at a much ...

US planemaker Boeing is heading into a busy week, with investors watching developments closely around its costly labour strike, as well as its latest quarterly results. More than 33,000 unionised ...